EGFR and neoplasm: Key oncogenic kinase drug targets include the PIK3CA, BRAF, and epidermal growth factor receptor (EGFR), which activates significant tumor cell signaling pathways and is related to the mutations and/or deletions in phosphatase and tensin homolog (PTEN), a phosphatase that negatively regulates PI3K [6, 7, 15].